YolTech Therapeutics Co., Ltd | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)	Calculi, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hyperoxaluria, Kidney Calculi, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Urinary Calculi, Urogenital Diseases, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, kidney disorder, metabolic disease, nephrolithiasis, primary hyperoxaluria, primary hyperoxaluria type 1, urinary system disorder, urolithiasis	Recruiting	Phase 2	2026-10-09		NCT07587021
Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)	Calculi, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hyperoxaluria, Kidney Calculi, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Urinary Calculi, Urogenital Diseases, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, kidney disorder, metabolic disease, nephrolithiasis, primary hyperoxaluria, primary hyperoxaluria type 1, urinary system disorder, urolithiasis	Recruiting	Phase 1	2026-08-20		NCT07776626
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy	Transthyroxin Amyloidosis Cardiomyopathy	Recruiting	Early phase 1	2025-02-14		NCT06082050